Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 Biomarker group BEFREE Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers. 29549180 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 Biomarker group BEFREE Antagonists of MDM2-p53 interaction are emerging anti-cancer drugs utilized in clinical trials for malignancies that rarely mutate p53, including melanoma. 29030058 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 Biomarker group BEFREE The two murine double minute (MDM) family members MDM2 and MDMX are at the center of an intense clinical assessment as molecular target for the management of cancer. 28673313 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 Biomarker group BEFREE Modification of p53 expression levels and its principle apoptosis and cell cycle regulatory partners, mouse double minute 2 homolog (MDM‑2) and p21, has been previously reported in various types of cancer. 28260096 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 Biomarker group BEFREE Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers. 28783173 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 GeneticVariation group BEFREE A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. 28083704 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.360 GenomicAlterations group CGI